NJ Ayuk Departs from Centurion Law Firm to Pursue Other Energy Sector Endeavors
— The renowned energy lawyer is setting his sights on novel ways to enhance the industry — JOHANNESBURG, Jan. 5, 2024 /PRNewswire/ — NJ Ayuk, an internationally recognized lawyer and thought leader, recently announced that he will be stepping down from his role as chief executive o
Katahdin Bankshares Announces Stock Buyback Program
HOULTON, Maine, Jan. 5, 2024 /PRNewswire/ — Katahdin Bankshares Corp. (OTCQX: KTHN), parent company of Katahdin Trust Company, a community bank founded in 1918 serving northern Maine and the greater Bangor and Portland regions, announced that its Board of Directors has approved a Stock Buyback
Rivus Pharmaceuticals Announces Completion of Enrollment in Phase 2a HuMAIN Trial of HU6
– Topline data readout from HuMAIN trial planned for mid-2024 – – Company presenting at 2024 J.P. Morgan Healthcare Conference on January 8 at 10 a.m. PT – CHARLOTTESVILLE, Va, and SAN FRANCISCO, Jan. 5, 2024 /PRNewswire/ — Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutic
KOCCA PAVILION PARTICIPATES AT CES 2024 AND HOSTS ‘KOCCA NIGHT’
SEOUL, South Korea, Jan. 5, 2024 /PRNewswire/ — Korea Creative Content Agency (KOCCA) is a government organization that fosters and promotes the Korean content industry in both domestic and global market. To contribute to the development of Korean content industry, KOCCA has supported Korean c
Cerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WESTMINSTER, Colo., Jan. 5, 2024 /PRNewswire/ — Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, today announced that Valeska Schroeder, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Confere
Bexion Pharmaceuticals, Inc. to Present at Biotech Showcase 2024
Company now enrolling a Phase 1b/2 study in 1st Line mCRC and a PK/PD study in CIPN COVINGTON, Ky., Jan. 5, 2024 /PRNewswire/ — Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy
Supplemental New Drug Application for Akeso’s Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
HONG KONG, Jan. 5, 2024 /PRNewswire/ — Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab (开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxali
Green Hills Software Is First Embedded Software Company to Receive ISO/SAE 21434 Automotive Cybersecurity Certificate
With this industry-leading achievement, Green Hills extends its proven pedigree of safe and secure foundational software for connected Software-Defined Vehicles (SDV) LAS VEGAS, Jan. 5, 2024 /PRNewswire/ — Green Hills Software, the worldwide leader in embedded safety and security, today announ
Endotronix Submits PMA Application for its Cordella Pulmonary Artery Sensor System
NAPERVILLE, Ill., Jan. 5, 2024 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the submission of a Premarket Approval (PMA) application for its Cordella™ Pulmonary Artery (PA) Sensor
NOTHING BUNDT CAKES® AND REESE’S® ARE BACK TOGETHER AGAIN … WITH MORE PEANUT BUTTER!
New limited-time flavor features Bundt Cake topped with REESE’S Peanut Butter Sauce DALLAS, Jan. 5, 2024 /PRNewswire/ — Nothing Bundt Cakes and REESE’S, the iconic candy duo of milk chocolate and peanut butter, are kicking off the year on a sweet note with a limited-time REESER